Diamyd terminates liquidity provider agreement

3/4/2010 2:20 AM EST

Due to increased turnover in the share Mangold Fondkommission AB will no longer act as liquidity provider in Diamyd Medical’s B-share. The current liquidity provider agreement will expire on March 5, 2010. A new liquidity provider has not been appointed.

Diamyd Medical

RSS

Diamyd Medical is a biopharmaceutical company focusing on development of pharmaceuticals for treatment of diabetes and its complications. The company’s most advanced project is the GAD-based drug Diamyd® against autoimmu...

CONTACT

Diamyd Medical
+46-8 661 00 26
http://www.diamyd.com

Recent Releases

Diamyd Medical's Phase II study in cancer pain fully recruited
5/22/2012 2:30 AM EST
Quarterly Report II 11/12
4/4/2012 2:30 AM EST
Diamyd Medical's Phase III study published in the New England Journal of Medicine
2/2/2012 2:30 AM EST
Quarterly Report I 11/12
1/25/2012 2:30 AM EST
Prevention study with Diamyd´s diabetes vaccine fully recruited
1/9/2012 2:30 AM EST

Diamyd terminates liquidity provider agreement

Diamyd Medical

Related documents

Recent Releases

Tags